Taiho Oncology

FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
FDA Clears Taiho’s Lonsurf in Metastatic Colorectal Cancer Ahead of Takeda, Hutchmed
BioSpace
Thu, 08/3/23 - 10:23 am
Taiho Oncology
Lonsurf
colorectal cancer
FDA
Takeda
Hutchmed
FDA greenlights Otsuka subsidiary's bile duct cancer drug
Endpoints
Mon, 10/3/22 - 10:04 am
Otsuka
Taiho Oncology
Lytgobi
bile duct cancer
FDA
FDA approves Taiho Oncology's pill for metastatic colorectal cancer
BioPharma Dive
Thu, 09/24/15 - 11:31 am
FDA
metastatic colorectal cancer
Taiho Oncology
Lonsurf